Clearmind Medicine (CMND) vs Ernexa Therapeutics (ERNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ernexa Therapeutics is the larger company by market cap ($4.1 million vs $3.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMND | ERNA |
|---|---|---|
| Share price | $6.60 | $2.49 |
| Market cap | $3.35M | $4.06M |
| 1-day change | 0.00% | +4.18% |
| EPS (TTM) | $-461.20 | $-13.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3,840.00 | $71.50 |
| 52-week low | $5.25 | $2.14 |
| Distance from 52-week high | -99.83% | -96.52% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1104.82% |
| Average volume | 70.89K | 472.81K |
| Shares outstanding | 507.40K | 1.63M |
| Employees | — | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Clearmind Medicine
CMND stock →Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
Healthcare · Biotechnology
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Healthcare · Biotechnology · 5 employees
CMND vs ERNA FAQ
Which is bigger, Clearmind Medicine or Ernexa Therapeutics?
Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $4.06M compared with $3.35M for Clearmind Medicine (CMND).
Are Clearmind Medicine and Ernexa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.